MGMT and glioblastoma: A phase II trial involving a small cohort of elderly patients with MGMT promoter-unmethylated glioblastoma had similar results110; however, the clinical significance of such PFS gains is unclear because the reliability of assessing progression by neuroimaging can be questioned and because data from the RTOG 0825 trial raised concerns of early cognitive decline in patients treated with bevacizumab109.